Management of OFF condition in Parkinson disease
Author:
Open Access
- 1 December 2023
- journal article
- research article
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 13 (6) , 289-297
Abstract
Parkinson disease (PD) impacts nearly 1 million individuals in the United States. Nearly every patient with PD will require therapy with dopamine in the form of levodopa as the disease progresses. In more advanced stages of the disease, patients will experience motor fluctuations and require adjustment to their medication regimens to maintain good control of their symptoms. During the last 10 years, several new therapeutic treatment options have come to the market to treat motor fluctuations and improve patient quality of life. Some of these agents represent additional options to previously available drug classes, such as the catechol-O-methyl transferase (COMT) inhibitor, opicapone, and monoamine-oxidase B-inhibitor (MAO-B inhibitor), safinamide, as well as new dosage forms for available therapeutics. One new agent, istradefylline, has a novel mechanism in the treatment of PD. The place in therapy for these newer therapeutic options will be explored through a series of patient cases. This article focuses on evidence-based recommendations for the use of these newer options in the management of patients experiencing OFF episodes.Keywords
This publication has 48 references indexed in Scilit:
- Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's diseaseMovement Disorders, 2011
- Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's diseaseMovement Disorders, 2011
- Clinical efficacy of istradefylline (KW‐6002) in Parkinson's disease: A randomized, controlled studyMovement Disorders, 2010
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing resultsMovement Disorders, 2008
- Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuationsMovement Disorders, 2008
- Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)Annals of Neurology, 2008
- Effect of Low Concentrations of Apomorphine on Parkinsonism in a Randomized, Placebo-Controlled, Crossover StudyArchives of Neurology, 2008
- Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single doseJournal of the Neurological Sciences, 2007
- Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestationsMovement Disorders, 2005
- Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activityPharmacological Research, 2004